Using an in vitro cell model for M-MDSCs, our results further support the evidence that targeting EP2 and EP4 possess a therapeutic value for the immune modulation of the host immune system, alleviate tumor-derived suppression and thus, promote the development of anti-tumor immunity. This evidence concerns the gene PTGER4 and neoplasm.